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INTRODUCTION
Carcinoma  of  the  esophagus  is  one  among  the  most  challenging 
problems confronted by the oncologic surgeon. Esophageal tumors are highly 
likely to result in early mortality owing to the likelihood of advanced disease at 
the time of diagnosis and the challenging nature of their treatment.  Survival 
rates have not improved significantly in 25 years despite the availability of new 
treatment modalities.
Squamous cell  carcinomas are  the most common malignancies  of  the 
esophagus worldwide. However adenocarcinomas of the esophagus and cardia 
are relatively common, particularly in  the western hemisphere.  The reported 
incidence of these cancers is increasing in the United States at a rate surpassing
that of any other cancer.
This study was undertaken to analyse the presentation of carcinoma of 
the  esophagus  at  the  Government  Rajaji  Hospital  and to  compare  that  with 
world literature.
AIMS OF THE STUDY
The aims of this study were to analyze and study
1. The incidence of ca esophagus age and sex wise.
2.  The clinical presentation of Ca esophagus.
3. The common sites of occurrence 
4. The pathological types 
5. The stage at presentation and 
6. The resectability of carcinoma esophagus at Govt Rajaji Hospital.
REVIEW OF LITERATURE
ANATOMY OF ESOPHAGUS
The esophagus commences at the cricopharyngeus muscle at the level of
the cricoid cartilage and extends 5 to 6 cm in the cervical region to enter the
thoracic inlet. The intrathoracic esophagus extends an additional 20 to 25 cm to 
the gastro esophageal junction.
Typically,  many  radiologists  and  surgeons  divide  the  esophagus  into 
thirds whereby the upper third extends from the cricopharyngeus to the superior 
portion of the aortic arch, the middle third extends from the aortic arch to the 
inferior  pulmonary  veins,  and the  distal  third  extends from the  level  of  the 
inferior pulmonary veins to the gastro esophageal junction.
BLOOD SUPPLY
The blood supply to the esophagus is segmental, with vessels extending 
into  the  esophagus  to  form  a  submucosal  vascular  plexus.  The  cervical 
esophagus is supplied primarily by the superior and inferior thyroid arteries, 
whereas  the  thoracic  esophagus  is  supplied  by  esophageal  arteries  arising 
directly from the aorta near the level of the carina; the distal esophagus and 
gastric cardia are  supplied primarily by the left gastric artery. Venous drainage 
from the  esophagus  is  into  the  azygous  and  hemiazygous  veins  as  well  as 
intercostal veins that ultimately drain into the azygous system 
LYMPHATICS
The esophagus contains abundant mucosal and submucosal lymphatics 
that communicate with lymphatic channels in the muscular layers to drain either 
directly through the esophageal wall to adjacent lymph nodes or to the thoracic 
duct. 
Lesions  in  the  upper third of  the  esophagus tend to  drain initially  to 
internal jugular, cervical, and supraclavicular nodes; in contrast, middle third 
lesions  drain  initially  to  paratracheal,  hilar,  subcarinal,  paraesophageal,  and 
pericardial nodal regions. 
Distal third tumors tend to drain to nodes along the lesser curvature, left 
gastric  artery,  and  celiac  axis.  However,  because  the  pattern  of  lymphatic 
drainage  is  primarily  longitudinal  rather  than  segmental,  extensive  regional 
dissemination  of  cancer  cells  may  occur  irrespective  of  the  location  of  the 
primary tumor. 
Celiac  nodal  metastases  have been observed in  10% of  patients  with 
upper  third  carcinomas,  and  nearly  45%  of  individuals  with  middle  third 
lesions;  approximately  30% patients  with  middle  or  lower  third  carcinomas 
have metastatic disease in deep cervical lymph nodes at presentation. 

CARCINOMA ESOPHAGUS
PREDISPOSING CONDITIONS
Tylosis
Tylosis  (focal  nonepidermolytic  palmoplantar  keratoderma)  is  a  rare 
disease  inherited  in  an  autosomal  dominant  manner  that  is  characterized  by 
hyperkeratosis of the palms and soles and esophageal papillomas. 
Patients  with this  condition exhibit  abnormal maturation of  squamous 
cells and inflammation within the esophagus and have extremely high risk of 
developing esophageal cancer. The tylosis esophageal cancer (TOC) gene has 
been mapped to 17q25 by linkage analysis of pedigrees associated with high 
risk of esophageal cancer development.
Plummer-Vinson/Paterson-Kelly Syndrome
Plummer-Vinson/Paterson-Kelly  syndrome  is  characterized  by  iron- 
deficiency  anemia,  glossitis,  kelosis,  brittle  fingernails,  splenomegaly,  and 
esophageal  webs.  Approximately  10%  of  individuals  with  Plummer-
Vinson/Paterson-Kelly  syndrome  develop  hypopharyngeal  or  esophageal 
epidermoid carcinomas. The mechanisms by which these tumors arise have not 
been fully defined, although nutritional deficiencies as well as chronic mucosal 
irritation from retained food particles at the level of the webs may contribute to 
the pathogenesis of these neoplasms. 
Caustic Injury
Squamous cell carcinomas may arise in lye strictures, often developing 
40 to  50 years  following caustic  injury.   The majority  of  these  cancers  are 
located  in  the  middle  third  of  the  esophagus.  The  pathogenesis  of  these 
neoplasms may be similar to that implicated in esophageal cancers arising in 
patients with Plummer-Vinson syndrome. 
These  cancers  are  often  diagnosed  late  due  to  the  fact  that  chronic 
dysphagia and pain due to the lye strictures obscure symptoms of esophageal 
cancer.
Achalasia
Achalasia  is  an  idiopathic  esophageal  motility  disorder  characterized 
by  increased  basal  pressure  in  the  lower  esophageal  sphincter,  incomplete 
relaxation of this sphincter following deglutition, and aperistalsis of the body of 
the esophagus. A 16- to 30-fold increase in esophageal cancer risk has been 
noted  in  achalasia  patients.  These   neoplasms  typically  are  squamous  cell 
carcinomas, believed to result from prolonged irritation from retained foods at 
the air-fluid interface in the midesophagus
Human Papillomavirus Infection
Several  studies  suggest  that  human  papillomavirus  (HPV)  may 
contribute to the pathogenesis of esophageal squamous cell cancers in high- 
incidence areas in Asia and South Africa. 
Prior Aerodigestive Tract Malignancy
Carcinomas  of  the  aerodigestive  tract  arise  as  the  consequence  of 
multistep processes in cancerization fields.  Patients with upper aerodigestive 
tract cancers develop second primary cancers at a rate of  approximately 4% per 
year.   Nearly  10%  of  secondary  neoplasms  arising  in  patients  with  prior 
histories of oropharyngeal carcinoma arise in the esophagus.
Barrett's Esophagus
Barrett's  esophagus  is  characterized  by  the  presence  of  columnar 
epithelium  lining  3  or  more  cm  of  the  distal  tubular  esophagus  in  the 
presence or absence of hiatal hernia.  Barrett's esophagus has been associated 
with a 30- to 40-fold increase in the risk of adenocarcinoma, the incidence of 
which increased at a rate of 10% per year during the 1980s
MOLECULAR BIOLOGY
Flow cytometric  and  molecular  analyses  of  dysplastic  squamous  and 
Barrett's  epithelia  have  revealed  that  esophageal  cancers  arise  via 
widespread  clonal  outgrowth  of  cells  exhibiting  aberrant  cell-cycle 
regulation. In general, genomic instability precedes the appearance of histologic 
abnormalities in esophageal mucosa, and the extent of cell-cycle derangements 
influences progression to malignancy in this setting.
Many of the oncogene and tumor suppressor gene mutations frequently 
observed in esophageal cancers and their precursor lesions perturb cell-cycle 
regulation by disrupting the G(1) restriction point.  
PATHOLOGY 
The  overwhelming  majority  of  esophageal  malignancies  may  be 
classified as either squamous cell carcinomas or adenocarcinomas. Squamous 
cell  carcinomas  account  for  the  vast  majority  of  cancers  arising  in  high-
incidence areas throughout the world. Approximately 60% of these neoplasms 
are located in the middle third of the esophagus, whereas 30% and 10% arise in 
the distal third or proximal third of the intrathoracic esophagus, respectively. 
Typically,  these  tumors  are  moderately  well  differentiated  and  often  are 
associated  with  contiguous  or  noncontiguous  carcinoma  in  situ,  as  well  as 
widespread submucosal lymphatic dissemination. 
Adenocarcinomas frequently arise in the context of Barrett's esophagus; 
as such, these tumors tend to be localized in the distal third of the esophagus 
and may be fungating or stenotic in appearance. Many of these tumors are well-
differentiated  adenocarcinomas,  and  the  vast  majority  are  associated  with 
intraepithelial neoplasia.  No significant survival differences have been noted in 
adenocarcinoma  patients  compared  with  similarly  staged  individuals  with 
squamous cell cancers. 
Several  rare cancers of the esophagus have been described,  including 
squamous  cell  carcinoma  with  sarcomatous  features,  as  well  as  adenoid 
cystic,  and  mucoepidermoid  carcinomas.   These  neoplasms  are 
indistinguishable clinically and prognostically from the more common types of 
esophageal carcinomas.
CLINICAL PRESENTATION
Because it  lacks  a  serosal  coat,  the  esophagus is  able  to  distend and 
accommodate  considerable  intraluminal  tumor  growth  before  deglutition  is 
affected;  as  such,  50% of esophageal  cancer  patients  have locally  advanced 
unresectable disease or distant metastases at presentation. 
Dysphagia and weight loss are the initial  symptoms in approximately 
90% of patients presenting with esophageal cancer. Approximately 75% of the 
esophageal  circumference must  be  involved with  tumor  before  dysphagia  is 
experienced;  hence,  although  many  patients  relate  a  vague  discomfort  with 
swallowing for several months, dysphagia to solid foods may progress rapidly 
to total obstruction from circumferential tumor growth. Approximately 20% of 
patients  experience  odynophagia  (painful  swallowing).  Although  the  vast 
majority  of esophageal cancer  patients  present with weight loss,  cachexia is 
seen in less than 10% of these individuals.  Additional presenting symptoms 
may  include  dull  retrosternal  pain  resulting  from  invasion  of  mediastinal 
structures, cough, or hoarseness due to paratracheal nodal or recurrent laryngeal 
nerve  involvement.  Infrequently,  patients  may  present  with  pneumonia 
secondary to tracheoesophageal  fistula or  exsanguinating hemorrhage due to 
erosion of the esophageal neoplasm into the aorta.
DIAGNOSIS
Esophageal cancer should be suspected in any patient complaining of 
dysphagia  and  weight  loss.  A  thorough  history  should  be  ascertained, 
focusing on preexisting conditions, as well as tobacco and ethanol abuse, which 
are known to be associated with increased esophageal cancer risk.
Aspiration  cytology should  be  performed  on palpable  cervical  lymph 
nodes to rule out extrathoracic metastases.
Radiography:
Chest radiography and barium swallow should be performed; the barium 
swallow provides an inexpensive and important initial assessment of the extent 
of the disease within the esophagus and should include the entire esophagus as 
well as stomach and duodenum; double-contrast studies are preferable because 
they provide more precise evaluation of mucosal patterns and allow detection of 
small lesions that may be missed on single-contrast examination. 
Endoscopy:
Patients who are suspected to have a primary esophageal carcinoma on 
the  basis  of  history,  physical  examination,  or  radiographic  studies  should 
undergo esophagoscopy to establish tissue diagnosis and define the extent of 
the esophageal lesion. At the time of endoscopy, attention should focus on the 
identification  of  the  neoplasm  in  relation  to  cricopharyngeus,  the 
squamocolumnar  junction,  and  the  diaphragmatic  hiatus;  in  addition  the 
presence or  absence of satellite  lesions,  Barrett's  esophagus,  and esophagitis 
should be noted. Biopsies and brushings should be obtained from suspicious 
lesions;  the  combined  diagnostic  accuracy  of  these  two  procedures  exceeds 
90%. 
Vital  stains  including toluidine blue  or  Lugol's  iodine may be  useful 
to  guide  endoscopic  biopsies  in  situations  in  which  lesions  are  equivocal. 
Frequently, strictures are encountered that require dilation  to allow passage of 
the  endoscope and provide  temporary  relief  of  dysphagia.  Occasionally,  the 
esophagus  is  so  strictured  it  cannot  be  safely  dilated;  in  these  situations, 
multiple biopsies in four quadrants should be obtained, and the patients treated 
as  if  they  have  esophageal  carcinoma  irrespective  of  biopsy  results. 
Bronchoscopy  should  always  be  performed  in  patients  with  potentially 
resectable upper and middle third esophageal carcinomas to rule out recurrent 
laryngeal  nerve  involvement  and  to  identify  and  biopsy  suspicious  areas 
within  the  membranous  trachea  to  rule  out  impending  esophagorespiratory 
fistula.
CT:       
Once  a  tissue  diagnosis  of  esophageal  cancer  has  been  established, 
additional  studies  should  be  obtained  to  accurately  stage  the  disease 
according to American Joint Committee on Cancer criteria in order to ascertain 
prognosis and optimize treatment. Tumor length and the degree of obstruction 
appear to have less effect than the extent of wall penetration and lymph node 
metastases in determining survival of esophageal cancer patients. 
Computed tomography (CT) of the chest and upper abdomen should be 
obtained to evaluate the extent of disease within the chest and rule out visceral 
metastases  in  the  abdomen  Current  noninvasive  imaging  modalities  are 
imperfect regarding evaluation of local regional disease and detection of distant 
metastases  in  these  individuals.  Conventional  CT  scans  detect  the  primary 
tumor in 75% to 80% of cases; however, sensitivity for local regional nodal 
disease is only 50% to 70%. 
Furthermore, although CT scans may accurately predict resectability in 
as many as 75% of cases, they have not proven useful for assessing response to 
induction therapy in esophageal cancer patients. 
Endoscopic ultrasound:
Endoscopic ultrasonography (EUS) has been advocated as a means to 
enhance the accuracy of staging of esophageal cancers. Several studies indicate 
that in experienced hands, EUS accurately assesses wall involvement in 50% to 
90% of tumors and mediastinal lymph node status in 67% to 100% of patients 
with  localized  esophageal  cancers.  EUS  may  be  a  valuable  noninvasive 
means  to  detect  celiac  nodal  metastases  in  esophageal  cancer  patients 
(sensitivity,  70%  to  80%,  and  specificity,  88%  to  98%).  However,  the 
accuracy  of  EUS  is  highly  dependent  on  the  expertise  of  the 
ultrasonographer;  an  incomplete  or  erroneous  assessment  of  lymph  node 
metastases, invasion of adjacent organs, and poor staging of early carcinomas 
have been reported.  Furthermore,  EUS has  limited value in  staging patients 
with  high-grade  obstruction  or  assessing  response  to  induction  therapy  in 
esophageal cancer patients. 
PET scans:
[**18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) 
scans  have been used for  staging patients  with locally  advanced esophageal 
cancers. PET scans may enhance the sensitivity for imaging small metastatic 
deposits in the mediastinum and abdomen. Further refinement may enable the 
diagnostic accuracy of PET scans to equal that achieved by minimally invasive 
staging techniques. 
Furthermore, preliminary data suggest that PET scans may      prove to 
be valuable for assessing response to induction therapy in      esophageal cancer 
patients  in contrast to CT scans or EUS, which appear to be unreliable for 
evaluation of treatment response in these individuals.   Use of these imaging 
modalities may enhance the accuracy of staging in esophageal cancer patients, 
thereby  improving  stratification  of  individuals  for  multimodality  treatment 
protocols.
STAGING
The modern staging of carcinoma of the esophagus is based on 
the  tumor/node/metastasis  (TNM)  classification  developed  by  the American 
Joint Committee on Cancer  
Clearly,patient  outcomes  depend on  the  initial  stage  of  the  cancer  at 
diagnosis.  Although surgical  pathology yields the most  accurate staging,  the 
advent of better imaging techniques, including endoscopic ultrasonography, has 
improved  preclinical  staging;  (18)F-fluorodeoxyglucose  positron  emission 
tomography (FDG-PET) may be useful for detection of distant lymphatic and 
hematogenous
metastases. 
At diagnosis, nearly 50% of patients have cancer that extends beyond the 
locoregional  confines  of  the  primary.  Fewer  than  60%  of  patients  with 
locoregional cancer can undergo a curative resection. Nearly 70% to 80% of 
resected  specimens  harbor  metastases  in  the  regional  lymph  nodes.  Thus, 
clinicians are often dealing with advanced-stage carcinoma in newly diagnosed 
patients. 
(American Joint Committee on Cancer (AJCC) TNM Classification
of Carcinoma of the Esophagus*)
 Primary Tumor (T)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ
T1 Tumor invades lamina propria or submucosa
T2 Tumor invades muscularis propria
T3 Tumor invades adventitia
T4 Tumor invades adjacent structures
 Regional Lymph Nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
Distant Metastasis (M)
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
Tumors of the lower thoracic esophagus
M1a Metastasis in celiac lymph nodes
M1b Other distant metastasis
Tumors of the midthoracic esophagus:
M1a Not applicable
M1b Nonregional lymph nodes and/or other distant
Metastasis
Tumors of the upper thoracic esophagus
M1a Metastasis in cervical nodes 
M1b Other distant metastasis
Stage Grouping
Stage 0   Tis N0 M0
Stage I     T1 N0 M0
Stage IIA  T2 N0 M0 
                 T3 N0 M0
Stage IIB   T1 N1 M0
                   T2 N1 M0
Stage III      T3 N1 M0
                   T4 Any N M0
Stage IV      Any T Any N M1
Stage IVA      Any T Any N M1a
Stage IVB       Any T Any N M1b 
Histologic Grade (G)
GX Grade cannot be assessed
G1 Well differentiated
G2 Moderately differentiated
G3 Poorly differentiated
G4 Undifferentiated
TREATMENT
The  treatment  of  choice  for  patients  with  esophageal  cancer  is 
controversial. Esophagectomy remains the standard of care; however, its role 
has  been challenged due  to  the  generally  poor  outcomes  following surgical 
resection alone in  patients  who typically  have locally  advanced disease  .  A 
survey of community care practice patterns between 1988 and 1993 revealed an 
increase  in  the  use  of  chemoradiotherapy  relative  to  surgery  as  primary 
management of esophageal cancer. 
Currently, in many institutions, primary resection is deferred in favor of 
combined  modality  therapy  with  or  without  adjuvant  esophagectomy.  The 
routine use of combined modality treatment outside the realms of controlled 
clinical trials is troublesome since most randomized trials have not shown a 
survival  advantage  of  various  induction  regimens  compared  with 
esophagectomy alone. Furthermore, there is considerable controversy within the 
surgical literature as to what represents the appropriate operation for patients 
with esophageal cancer ; the debate focuses primarily on the need for and the 
extent  of  lymph  node  dissection  during  esophagectomy  for  cancer.  The 
following discussion summarizes the current status of surgery, chemotherapy, 
radiation  therapy,  and  combined  modality  regimens  in  the  treatment  of 
esophageal cancer.
 Primary therapy of esophageal cancer is either surgical or nonsurgical. 
Although  the  overall  results  of  these  approaches  are  similar,  the  patient 
populations  selected  for  treatment  with  each  modality  are  usually  different, 
resulting in a potential selection bias against nonsurgical therapy. Patients with 
poor  prognostic  features,  including  those  with  comorbid  conditions,  or 
unresectable or metastatic disease, are more commonly selected for treatment 
with nonsurgical therapy.    
SURGICAL RESECTION
Surgical Approaches
Various surgical  approaches may be used,  depending on the size and 
location  of  the  primary  tumor  and  on  the  preferences  of  the  surgeon.  The 
optimal location of the anastomosis has been debated. The advantages of the 
cervical  anastomosis  include  more  extensive  resection  of  the  esophagus, 
possibility of avoiding thoracotomy, less-severe symptoms of reflux, and less-
severe complications related to anastomotic leak. Advantages of the thoracic 
anastomosis include a lower incidence of anastomotic leak and lower stricture 
rate. 
Although some surgeons prefer the colon interposition, most surgeons 
use  the  stomach  as  the  conduit  to  replace  the  esophagus  after 
esophagogastrectomy. Colon interposition is usually reserved for patients who 
have had previous gastric surgery or other procedures that have devascularized 
the  stomach.  The use  of  the  gastric  conduit  simplifies  the  procedure  and is 
associated  with  equivalent  patient  satisfaction  and  fewer  postoperative 
complications 
Several approaches are acceptable for esophagogastrectomy. Ivor- Lewis 
esophagogastrectomy uses abdominal and right thoracic incisions, with upper 
thoracic  esophagogastric  anastomosis  (at  or  above  the  azygos  vein. 
Mobilization of the stomach for use as the conduit is performed, with dissection 
of the celiac and left gastric lymph nodes, division of the left gastric artery, and 
preservation of the gastroepiploic and right gastric arteries. This approach may 
be used for lesions at any thoracic location, but margins may be inadequate for 
tumors in the middle esophagus.  
Transhiatal esophagogastrectomy is performed using abdominal and left 
cervical incisions. The mobilization of the stomach for use as the conduit is 
performed  as  in  the  Ivor-Lewis  esophagogastrectomy.  This  procedure  is 
completed via the abdominal incision, and the gastric conduit is drawn through 
the  mediastinum  and  exteriorized  in  the  cervical  incision  for  the 
esophagogastric  anastomosis.  This  approach may be used for  lesions  at  any 
thoracic location; however, transhiatal dissection of large, middle esophageal 
tumors adjacent to the trachea is difficult and may be hazardous.
Left  thoracoabdominal  esophagogastrectomy  uses  a  contiguous 
abdominal  and  left  thoracic  incision,  through  the  eighth  intercostal  space. 
Mobilization of the stomach for use as the conduit is performed as described 
previously,  and  esophagectomy  is  accomplished  via  the  left  thoracotomy. 
Esophagogastric anastomosis is performed in the left chest, usually just superior 
to  the  inferior  pulmonary  vein,  although it  may be  performed higher  if  the 
conduit is tunneled under the aortic arch. This approach may be used for lesions 
in the distal esophagus.
Minimally invasive esophagectomy might decrease morbidity; however, 
only  a  few  series  have  been  published. Open  surgery  should  remain  the 
standard until studies show the advantages of minimally invasive approaches. 
Transhiatal Esophagectomy
Transhiatal  esophagectomy  entails  extirpation  of  the  intrathoracic 
esophagus through the esophageal hiatus of the diaphragm without the need for 
a thoracotomy incision. An upper abdominal incision and a low-neck incision 
are required to isolate the esophagus at either end. The organ is next carefully 
stripped  from  its  mediastinal  attachments  and  removed.  The  prepared 
esophageal  substitute,  usually  a  greater  curvature  gastric  tube,  is  advanced 
across the esophageal bed in  the posterior  mediastinum, and gastrointestinal 
continuity is restored by an end-to-side esophagogastrostomy in the neck. No 
attempt is made to perform a systematic lymph node dissection apart from the 
few parahiatal  nodes removed with the specimen.  Occasionally, sampling of 
readily accessible celiac and periesophageal nodes is performed. 
Standard Transthoracic Esophagectomy
Transthoracic  esophagectomy is  probably  the  most  widely  performed 
operation  for  cancer  of  the  esophagus  worldwide.  The  procedure  can  be 
carried  out  through  a  right  or  left  thoracotomy  incision  depending  on  the 
preference of the surgeon and the location of the tumor within the esophagus. 
Generally, a right thoracotomy is required for adequate exposure of tumors in 
the  middle  or  upper  third  that  are  anatomically  intimately  related  to  the 
membranous trachea or the arch of the aorta. 
Tumors located at the gastroesophageal junction or in the lower third 
of  the  esophagus  can  be  usually  approached  through  a  left  thoracotomy 
incision.  A left  sixth  interspace  incision  provides  excellent  exposure  of  the 
lower mediastinum, and a semicircular diaphragmatic incision performed 1 inch 
from the costal  arch allows access to the upper abdomen. The esophagus is 
mobilized from its mediastinal bed along with adjoining periesophageal as well 
as  lesser curvature lymph nodes;  no radical  mediastinal  or upper abdominal 
lymphadenectomy is performed. Gastrointestinal reconstruction is subsequently 
achieved  by  preparation  of  the  esophageal  substitute  (usually  stomach)  and 
advancing  it  to  the  neck  for  a  cervical  anastomosis.  Patients  operated  on 
through a right thoracotomy require a laparotomy to prepare the gastric tube 
and  pass  it  across  the  posterior  mediastinum  or  retrosternal  space  for  a 
cervical anastomosis. In patients operated on through a left thoracotomy, the 
esophagus  is  mobilized  along  its  course  in  the  supra  aortic  posterior 
mediastinum  well  into  the  neck.  The  prepared  gastric  tube  is  then  passed 
underneath the  aortic  arch and attached to  the  esophageal  stump. Following 
reattachment  of  the  diaphragm and closure  of  the  thoracotomy, a  small  left 
cervical incision is performed to retrieve the esophagus and the gastric tube. A 
cervical incision is then performed and the previously mobilized esophagus and 
gastric tube are easily delivered to the neck for a cervical anastomosis.
Comparison of Transhiatal and Transthoracic Esophagectomy
Several  retrospective  studies  have  shown  little  difference  in  the 
operative  mortality  and  morbidity  between  transhiatal  and  transthoracic 
esophagectomy with limited lymph node dissection 
En Bloc Esophagectomy
The deep location of the esophagus within the narrow confines of the 
mediastinum  and  the  lack  of  a  well-defined  mesentery  have  generally 
precluded  the  application  of  en  bloc  resection  to  patients  with  esophageal 
carcinoma.  The basic  principle  of  the  operation is  extirpation of  the  tumor-
bearing esophagus within a wide envelope of adjoining tissues that include both 
pleural surfaces laterally and the pericardium anteriorly where these structures 
are  intimately  related  to  the  esophagus.  The  lymphatics  wedged  dorsally 
between  the  esophagus  and  the  aorta,  and  the  thoracic  duct  throughout  its 
mediastinal  course,  are  resected  en  bloc  with  the  specimen.  This  posterior 
mediastinectomy necessarily results in a complete mediastinal node dissection 
from the tracheal bifurcation to the esophageal hiatus. Additionally, an upper 
abdominal  lymphadenectomy  is  performed  including  the  common  hepatic, 
celiac, left gastric, lesser curvature, parahiatal, and retroperitoneal nodes. The 
purpose of this extended resection is to maximize locoregional control of the 
primary tumor. Critics have argued that the en bloc procedure is associated with 
a  high  operative  mortality  and  morbidity  without  an  apparent  survival 
advantage.
Three-Field Lymphadenectomy
Three-field lymph node dissection for carcinoma of the esophagus has 
been practiced by Japanese surgeons since the  early  1980s.  This  effort  was 
initially prompted by studies showing that the cervical lymph nodes were the 
site of tumor recurrence in 30% to 40% of patients in whom a curative resection 
had  been  performed.  The  extended  procedure  included  dissection  of  the 
cervical, mediastinal, and upper abdominal nodes in patients with carcinoma of 
the thoracic and abdominal esophagus.
IVOR – LEWIS  ESOPHAGECTOMY
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POST OP SPECIMENS
RADIATION THERAPY
It  may be used  either  as  external  beam irradiation  or  as  intraluminal 
brachytherapy. External beam therapy maybe used with a curative intent, in the 
adjuvant,neoadjuvant  settings  and  with  concurrent  chemotherapy  as 
chemoradiation.  External  beam  radiation  may  also  be  used  as  a  palliative 
measure in advanced tumors.
RT alone should generally be reserved for palliation or for patients who 
are  medically  unable  to  receive  chemotherapy.  Alternative  radiation 
approaches, such as hypoxic cell sensitizers and hyperfractionation, have not 
resulted in a clear survival advantage. Experience with intraoperative radiation 
as an alternative to external-beam radiation is limited. Conformal and intensity-
modulated  RT  are  currently  being  investigated.  In  the  adjuvant  setting, 
randomized  trials  do  not  show  a  survival  advantage  for  preoperative  or 
postoperative RT alone. versus surgery alone for esophageal cancer. This meta-
analysis found that neoadjuvant chemoradiation and surgery improved 3- year 
survival  and  reduced  local-regional  cancer  recurrence  when  compared  with 
surgery alone. Such analyses only suggest that preoperative approaches need 
continued investigations.
Brachytherapy
Intraluminal  brachytherapy  allows  the  escalation  of  the  dose  to  the 
primary tumor while protecting the surrounding dose-limiting structures such as 
the lung, heart, and spinal cord. A radioactive source is placed intraluminally 
via endoscope or a nasogastric tube. 
Brachytherapy  has  been  used  both  as  primary  therapy  (usually  as  a 
palliative modality), as well as boost following external-beam radiation therapy 
or combined modality therapy. It  can be delivered by high dose-rate or low 
dose-rate. As a single therapy, brachytherapy is used as a palliative modality 
and results  in a local  control  rate of 25% to 35% and a median survival of 
approximately 5 months.
ENDOLUMINAL PALLIATION TECHNIQUES
As  previously  discussed,  surgery  remains  the  standard  of  care  for 
patients  with  resectable  neoplasms;  however,  many  esophageal  cancer 
patients are inoperable due to locally advanced or distant metastatic disease. 
Although  chemotherapy  and  radiation  therapy  are  typically  used  to  palliate 
unresectable disease, many individuals require additional measures to relieve 
dysphagia and pain. 
Esophageal  dilation  frequently  can  alleviate  esophageal  obstruction 
secondary to malignancy; however, results usually are temporary, and patients 
require repeated treatments. Safe and effective palliation can be achieved by 
endoluminal stents, laser, or photodynamic therapy (PDT) techniques.
CHEMOTHERAPY
A  variety  of  single  agents  and  combination  regimens  have  been 
evaluated  in  patients  with  recurrent  or  metastatic  carcinoma  of  the 
esophagus.  These  patients  often  have  a  high  tumor  burden  and  poor 
performance  status  with  little  prospect  for  prolongation  of  survival. 
Bleomycin, 5-fluorouracil (5-FU), mitomycin, and cisplatin (CDDP) have been 
used most often because of their single-agent activities and their additive or 
synergistic effects with radiation.
Chemotherapy can provide transient  palliation for  some patients  with 
advanced locoregional  carcinoma, but other approaches (including combined 
modality therapy) are more effective for this purpose.
The list of established chemotherapeutic drugs active against esophageal 
carcinoma  is  small.  In  the  past  25  years,  only  16  cytotoxic  drugs  were 
investigated  systematically  against  metastatic  esophageal  carcinoma.  The 
activity  of  nearly  all  these  agents  was  established  against  squamous  cell 
histology. Cisplatin has been considered one of the most active agents, with a 
single-agent response rate consistently in the range of 20% or greater. Older 
agents considered to be active include 5-FU, mitomycin, cisplatin, bleomycin, 
methotrexate, mitoguazone, doxorubicin, and vindesine. Newer agents that have 
shown activity include paclitaxel, docetaxel, vinorelbine, oxaliplatin with 5-FU, 
lobaplatin, irinotecan, nedaplatin, and gefitinib. 
Combination Chemotherapy
Only in more recent years have combination regimens been evaluated in 
patients  with  adenocarcinoma.  The  two-drug  combination  of  cisplatin  (100 
mg/m**2 day 1) and 5-FU (1000 mg/m**2/d continuous infusion for 96 to 120 
hours)  is  the  regimen  most  commonly  used  to  treat  patients  with  either 
squamous or adenocarcinoma histology.
Combination chemotherapy for metastatic carcinoma of the esophagus 
continues to evolve. Compared with adenocarcinoma, squamous cell carcinoma 
appears to be more sensitive to chemotherapy, chemoradiation, or radiotherapy; 
however,  the  longterm  outcome  is  not  different  for  patients  with  the  two 
histologic   types.  The combination of  5-FU plus  cisplatin is  considered  an 
acceptable  therapy.  It  is  the  most  investigated  and  most  commonly  used 
regimen for patients with carcinoma of the esophagus. Reported response rates 
to this combination vary between 20% and 50%. Paclitaxel combined with 5-
FU  and  cisplatin  has  demonstrated  activity  in  patients  with  squamous  cell 
carcinoma  and  adenocarcinoma.  In  addition,  the  combination  of  irinotecan 
(CPT-11) and cisplatin appears to have activity, particularly against squamous 
cell carcinoma of the esophagus
Although  combination  chemotherapy  often  results  in  higher  response 
rate, it can be associated with higher morbidity.
TREATMENT RECOMMENDATIONS AND FUTURE 
DIRECTIONS
Although  individuals  occasionally  are  diagnosed  early  due  to 
participation  in  screening  protocols,  the  vast  majority  of  patients  with 
esophageal cancer present with either locally advanced (stages IIB or III)  or 
inoperable metastatic disease. Esophagectomy remains the standard of care for 
patients  who  can  tolerate  resection.  Available  data  from  well-designed 
prospective  randomized  trials  do  not  support  the  routine  use  of  induction 
chemotherapy in resectable patients. 
Furthermore,  there are no convincing data that  justify the routine use 
of chemotherapy following esophagectomy. Radiation therapy has no proven 
benefit as the sole modality in the induction setting, and current data indicate a 
potential benefit of this treatment modality in patients with positive resection 
margins, but not in completely resected individuals irrespective of nodal status. 
Limited data suggest that combined chemoradiation therapy may be beneficial 
in  the  induction  setting  in  resectable  patients,  particularly  in  individuals 
achieving  pathologic  complete  responses;  surgery  remains  an  important 
component  of  these  aggressive  protocols  since  no  other  modality  enables 
accurate assessment of response to induction therapy, and no other intervention 
can enhance local control in this setting.
 Patients  with  unresectable  cancers  should  be  palliated  with 
chemoradiation therapy
BEST SUPPORTIVE CARE
Medically unfit  patients or those who develop an unresectable disease 
may be offered brachytherapy, laser therapy, PDT, or any other components of 
best  supportive  care  including  esophageal  dilatation,  pain  control,  enteral 
feeding, and/or therapy to control bleeding . 
For  patients  with  metastatic  carcinoma,  only  palliative  care  is 
appropriate.  Whether  to  offer  best  supportive  care  alone  or  together  with 
chemotherapy should be based on the patient's performance status. Patients with 
better performance status may be offered best  supportive care alone or with 
chemotherapy.
The  constituents  of  best  supportive  care  depend  on  the  patient's 
symptoms. In the case of esophageal obstruction, the patient may be offered a 
stent placement,  laser surgery, PDT, radiotherapy, or a combination of these 
methods, as appropriate. Esophageal dilatation may also be useful. For patients 
requiring nutritional support,  enteral feeding may be warranted. Pain control 
may be achieved with the use of radiotherapy plus pain medications. Similarly, 
surgery or radiotherapy and/or endoscopic therapy may be indicated in patients 
with brisk bleeding from the carcinoma.
Salvage Therapy
Salvage therapy can range from aggressive intervention with curative 
intent  in  patients  with  locoregional  relapse  to  therapy  intended  strictly  for 
palliation in patients for whom cure is not a possibility. For patients with local 
relapse  who  have  not  received  RT  or  chemotherapy,  RT  plus  concurrent 
chemotherapy (5-FU/cisplatin) is preferred; other options include endoscopic 
therapies or surgery. For example, re-resection can be considered in selected 
patients with anastomotic recurrences. For patients who develop a resectable 
locoregional  relapse  after  chemoradiotherapy  but  have  not  had  surgery,  the 
clinician should determine whether the patient is medically fit for surgery and if 
the relapse is technically resectable. If both of these criteria are met, surgery 
remains  an  option.  If  the  patient  has  another  relapse  after  surgery,  the 
carcinoma  should  be  considered  incurable  and  the  patient  should  receive 
palliative  therapy.  Medically  unfit  patients  or  those  who  develop  an 
unresectable  relapse  after  chemoradiotherapy may be offered  brachytherapy, 
laser therapy, PDT, or any other components of best supportive care including 
esophageal dilatation, pain control,  enteral feeding, and/or therapy to control 
bleeding.
For  patients  with  metastatic  carcinoma,  only  palliative  care  is 
appropriate.  Whether  to  offer  best  supportive  care  alone  or  together  with 
chemotherapy should be based on the patient's performance status. Patients with 
a  Karnofsky  performance  score  of  60  or  less  should  be  offered  only  best 
supportive care.  Patients with better performance status may be offered best 
supportive care alone or with chemotherapy. 
Follow-up
All  patients  should  be  followed  systematically.   For  asymptomatic 
patients, follow-up should include a complete history and physical examination 
every  4  months  for  1  year,  then  every  6  months  for  2  years,  and annually 
thereafter. A complete blood count, multichannel serum chemistry evaluation, 
and a chest radiograph should be obtained as clinically indicated. Endoscopy 
and other radiologic studies should also be considered as clinically indicated 
(eg, persistent or recurrent dysphagia). In addition, some patients may require 
dilatation of an anastomotic or a chemoradiation-induced stricture. 
OUTCOMES 
One of the major developments in the surgical  therapy of Carcinoma 
esophagus  has  been  the  marked  improvement  in  surgical  morbidity  and 
mortality as a result of improvement in surgical morbidity and mortality as a 
result  of  improvement  in  surgical  techniques,  patient  selection  and  support 
systems.
Surgical  management  of  patients  with  Carcinoma  esophagus  may 
include staging,  resection with curative intent and palliative techniques.  The 
intent of surgery should be to achieve R0 resection. Palliative surgery should be 
avoided in patients with clearly unresectable or advanced cancer who can be 
effectively palliated with non surgical modalities. 
The  5  year  survival  after  R0  resection  is  15-20  %  and  the  median 
survival  after  R0  resection  is  approximately  18  months.  No  difference  in 
survival was observed between groups treated with surgery alone or induction 
therapy followed by surgery. 
Long term outcomes  depend on the  initial  stage  of  the  carcinoma at 
presentation. Stage I, II and III cancer are considered potentially respectable. 
Aggressive preoperative staging  (including esophageal ultra sound, PET and 
molecular biologic techniques) may result in improved prognostic stratification, 
improved patient selection for surgical therapy and improved over all survival.
Selecting patients for surgery includes assessing whether they are medically fit 
and the extent of their cancer.  Patients with advanced comorbidity including 
severe cardiac and pulmonary disease, are not considered for resection but may 
benefit from non invasive palliative interventions. However most patients with 
early stage cancer will tolerate resection.
MATERIALS AND METHODS
This study consists of 152 cases of Ca esophagus who were admitted at 
Government Rajaji Hospital between April 2003 and September 2005. These 
patients were examined in detail as per the Performa prepared for this study. 
The were investigated to confirm the pathological diagnosis and to assess the 
extent and stage of the disease and resectability.
Lower mid third and lower third growths were submitted for  surgery 
after  resectability  was  assessed  by  CT  scanning.  Of  the  48  patients  thus 
submitted for surgery only 19 had resectable growths. 16 patients underwent 
Transhiatal esophagectomy and 3 underwent lvor Lewis esophagectomy.        
Post – operatively they were followed up closely until discharge and then 
at weekly intervals for 8 weeks.
Other patients who had unresectable disease were given external Beam 
Radiotherapy  with  or  without  feeding  gastrostomy.  Patients  with  metastatic 
disease and those with poor performance status were just given supportive care.
RESULTS OF THE STUDY
Incidence  of  Ca  esophagus  was  more  common in  males  with  a  M:F 
incidence ratio of 3.5:1.
Sex Incidence 
118
34
Male 
Female
Maximum incidence was in the 6th followed by 7th decades. 
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In the study it was found the maximum incidence in 5 th decade for male 
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Dysphagia was the most common presenting symptom seen in 94% of 
the patients. Weight loss and anorexia were also common symptoms present in 
70% of the patients other symptoms seen were regurgitation of food in 42%, 
recurrent respiratory injections and pneumonia in 18% of the patients. Cough 
and hoarseness of voice was seen in 12% of patients, odynophagia in 8% and 
Gastrointestinal bleed was a rare feature seen in 2% of patients.
Symptoms
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Dysphagia 143 94%
Odynophagia / Pain 12 08%
Regurgitation 64 42%
Resp. Infection 27 18%
GI bleed 3 2%
Weight loss / anorexia 106 70%
Cough and hoarseness 23 12%
Though incidence of distal esophageal tumours is increasing worldwide, 
mid third tumours were more common in this study making up to 40% of the 
cases. Upper third tumour were next common making up 32% and lower third 
tumours were least common making up 28% of the total cases.
Tumor site
32%
40%
28%
Upper 1/3 Mid 1/3 Lower 1/3
Upper 1/3 49 32%
Mid 1/3 61 40%
Lower 1/3 42 28%
Among  the  histological  types,  adenocarcinoma  and  Squamous  cell 
Carcinoma were the only 2 types encountered. Despite the increasing incidence 
of adenocarcinoma in the western countries, Squamous cell histology remained 
the predominant type seen in 135 (89%) of the patients. Adenocarcinoma was 
seen in only 17 (11%) of the patients.
Histology
89%
11%
Squamous cell Carcinoma Adenocarcinoma  
The  presentation  of  carcinoma  of  the  esophagus  was  rather  late.  No 
patients, presented with stage I disease. Only 10% patients presented with stage 
II  disease.  Majority  of  the  patients  presented  with  advanced  disease  where 
treatment was mainly palliative rather than curative. Majority of the patients 
(61%)  presented  with  stage  III  disease,  i.e.  locally  advanced  disease.  The 
remainder (29%) presented with metastatic i.e. stage IV disease.
Stage at Presentation
Stage I 0
Stage II A – 7  
B – 9       = 16
 10%
Stage III 92 61
Stage IV 44 29%
          
Resectability rate was very poor (12.5%) in our study. Only 10.5% of the 
patients  could  be  taken up for  Transhiatal  esophagectomy and 2% for  Ivor 
Lewis  thoracoabdominal  resections.  Majority  of  the  patients  (87.5%)  had 
unresectable disease.
Of  those  with  unresectable  disease  93  were  given  palliative  external 
beam Radiotherapy with or without Feeding Gastrostomy based on their level 
of  Dysphagia.  40  patients  who  had  either  metastatic  disease  or  poor 
performance status were offered supportive care with pain relief and enternal 
nutrition through’ a feeding gastrostomy where appropriate.
Treatment offered 
A. Surgical Resection 19
1. Transhiatal esophagectomy 16
2. Ivor Lewis esophagectomy   3
B. External RT 93
C. Supportive Care 40
(FG / RT Feeding / pain relief)
  
Post -  op Complications
On following up the operated patients, complications were encountered 
in 75% patients which included a mortality rate of 10.5%, one of which was due 
to anastamotic leak. Anastamotic leak was encountered in 11% patients, one of 
which was fatal. (in a patient post Ivor - Lewis esophagectomy). Pulmonary 
complaints were encountered in 40% patients. Haemorrhage was encountered in 
5% patients which was significant requiring re opening. Reflux was noted in 
2% patients and could be managed conservatively.
Complication n = 19
Mortality 2 (10.5%)
Pulmonary complications 8 (42%)
Haemorrhage 1 (53%)
Reflux (21%)
DISCUSSIONS
In this study, on analysis of the cases of carcinoma esophagus admitted 
at GRH it was seen that the disease is more prevalent among the males. (M:F – 
3.5:1) which is similar to the incidence in western countries. (In the U.S.  M:F – 
4:1)  (Ref 1).
The peak age of incidence was the sixth decade followed next by the 7 th 
decade which is similar to the incidence world wide (Ref 2).
On analyzing the symptoms at presentation it was seen that Dysphagia 
was the most common presenting symptom (94%), along with weight loss and 
anorexia (70%). This correlates cell with international statistics. (Ref 3)
Symptoms of Ca esophagus and cardia.(Ref-3)
Dysphagia 85.4%
Weight loss 60.9%
Pain 26.5%
Regurgitation 22.8%
Hoarseness 4.4%
Cough 2.5%
(N = 907)
 The  commonest  site  of  incidence  was  the  mid  third  (40%)  of  the 
esophagus in this study followed by upper third (32%). Lower third tumours 
were  least  common  (28%).  This  differs  from  western  literature  where  the 
reported commonest site of incidence is the lower third making up 55% of the 
total  tumors,  followed only by mid  third which make up 37%. Upper third 
tumours were rare (9%). ( Ref 4, 5,6). 
Adenocarcinomas of the esophagus and cardia are relatively common in 
the Western hemisphere. The reported incidence of these cancers is increasing 
in the  United States  at  a  rate surpassing that  of  any other  cancer.  However 
Squamous cell carcinomas are the most common histological type of carcinoma 
esophagus worldwide. (Ref.7,8,9,10). In this study, Squamous cell carcinoma 
was the predominant histology forming 89% of the tumors. The remaining 11% 
were Adenocarcinomas.
Presentation with carcinoma oesophagus was late in this study, majority 
presenting  with  either  locally  advanced  or  metastatic  disease  (80%).  This 
correlates well but is higher than in western studies where the presentation with 
advanced disease varied  from 60 – 75%. (Ref.9,10,11,12).
Overall Resectability rate was dismally low in this study (12.5%) which 
was much lower than in  international  studies  where it  varied from (35% to 
70%) (Ref. 11,12,13).
Post- op complications were encountered in 75% patients, which were 
major causing mortality or surgical intervention in 15%. Anastamotic leak rate 
was (10.5%). Pulmonary complications were encountered in 42% patients and 
was fatal in 5%. This complication rate was similar to that in publications from 
various centers. (Ref 12,13).
CONCLUSIONS
1. Incidence of Carcinoma esophagus in more common in males 
2. Maximum incidence is in the 6th decade followed by the 7th decade.
3. Dysphagia  and  weight  loss  are  the  most  common  but  late  presenting 
features
4. Most Common site of presentation is in the middle third in our population
5. Squamous cell Carcinoma still remains the predominant histological variety 
in our population
6. Carcinoma esophagus has an aggressive behaviors and usually presents in 
late stages with a low rate of resectability
7. Even with incurable  disease,  resection can offer  superior  palliation with 
restoration of swallowing
8. Transhiatal  resection  offers  comparable  results  to  transthoracic  resection 
with a lower operative risk.
